Profile data is unavailable for this security.
About the company
Pharmesis International Ltd. is a Singapore-based investment holding company. The Company is a pharmaceutical company engaged in the manufacturing of pharmaceutical products, including western medicine in the form of tablets and granules, among others, and traditional Chinese medicine (TCM) formulated products for the treatment of illnesses relating to the liver and gall bladder. It operates in three segments: Western drugs, which refers mainly to chemically formulated drugs marketed under the Kinna brand; TCM formulated drugs, which includes TCM marketed under the Longlife brand, and Distribution, which includes agency products and internally manufactured products marketed through the distribution arm. Its main products are ATT, Gulin Gansu and Er Ding granules. Its subsidiary, Chengdu Kinna Pharmaceutical Co., Ltd, is engaged in the development, manufacture, packaging and sale of western medicines and health tonic products.
- Revenue in SGD (TTM)8.52m
- Net income in SGD-925.54k
- Incorporated2003
- Employees--
- LocationPharmesis International LtdNo.8 Yingbin RoadCHENGDU ChinaCHN
- Websitehttps://www.pharmesis.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wellfully Ltd | 1.18m | -1.20m | 1.33m | 36.00 | -- | -- | -- | 1.13 | -0.003 | -0.003 | 0.0034 | -0.0034 | 0.377 | 0.3166 | 1.57 | -- | -38.36 | -175.88 | -- | -441.84 | 48.61 | -- | -101.74 | -266.08 | 0.2159 | -- | -- | -- | -42.78 | -5.87 | 12.98 | -- | 21.75 | -- |
| Parenteral Drugs (India) Ltd | 1.38m | -12.36m | 1.40m | -- | -- | -- | -- | 1.02 | -25.61 | -25.61 | 2.85 | -276.37 | 0.0162 | 4.17 | 0.9266 | -- | -14.52 | -17.82 | -- | -- | 35.67 | 40.22 | -898.77 | -191.93 | 0.055 | -0.5192 | -- | -- | -30.17 | -48.70 | 37.26 | -- | -- | -- |
| Melodiol Global Health Ltd | 17.62m | -31.93m | 1.48m | -- | -- | -- | -- | 0.084 | -0.2548 | -0.3762 | 0.1578 | -0.0172 | 0.6874 | 4.35 | 10.62 | -- | -124.57 | -102.92 | -387.77 | -152.32 | 15.38 | -- | -181.22 | -348.92 | 0.1594 | -6.71 | 1.73 | -- | 210.13 | 94.60 | -62.47 | -- | -46.82 | -- |
| Hexima Ltd | 174.27k | -677.10k | 1.50m | -- | -- | 0.6564 | -- | 8.62 | -0.0045 | -0.0045 | 0.0012 | 0.0152 | 0.0558 | -- | 0.2705 | -- | -21.67 | -72.85 | -26.54 | -193.37 | -- | -- | -388.54 | -213.09 | -- | -- | 0.00 | -- | 271.52 | -19.43 | 80.85 | -- | -- | -- |
| Pharmesis International Ltd. | 8.52m | -925.54k | 2.21m | -- | -- | 0.2316 | -- | 0.2592 | -0.0342 | -0.0342 | 0.3226 | 0.3454 | 0.4966 | 1.88 | 4.96 | -- | -5.34 | -6.47 | -9.13 | -10.21 | 45.61 | 48.72 | -10.75 | -13.39 | 0.5848 | -0.5693 | 0.2337 | -- | -9.40 | -6.64 | -39.27 | -- | -32.66 | -- |
| Ortin Laboratories Ltd | 554.29k | -663.83k | 2.27m | -- | -- | -- | -- | 4.10 | -5.02 | -5.02 | 4.10 | -- | -- | -- | -- | -- | -- | 0.376 | -- | 1.01 | -30.46 | 22.23 | -119.76 | 0.3017 | -- | -6.87 | -- | -- | -26.86 | -40.48 | 76.53 | -- | -- | -- |
| Saroja Pharma Industries India Ltd | -1.62bn | -1.62bn | 2.67m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -9.78 | -- | -6.97 | -- | -- | -- |
